

Supplemental online materials

Table S1. Treatments recorded after diagnosis of R/R AML in patients with R/R AML.

Line of therapy	All patients with R/R AML (N = 289)		<i>FLT3</i> ^{WT} at R/R diagnosis (N = 58)		<i>FLT3</i> ^{MUT} at R/R diagnosis (N = 14)		Unknown <i>FLT3</i> mutation status (N = 217)	
	Patients, ^a n (%)	Mean (SD) Ara-C dose (mg/m ²), number of treatment cycles	Patients, n (%)	Mean (SD) Ara-C dose (mg/m ²), number of treatment cycles	Patients, n (%)	Mean (SD) Ara-C dose (mg/m ²), number of treatment cycles	Patients, n (%)	Mean (SD) Ara-C dose (mg/m ²), number of treatment cycles
Second	237 (82.0)		54 (93.1)		13 (92.9)		170 (78.3)	
MA	58 (24.5)	201.8 (581.7), 1.5 (0.6)	17 (31.5)	105.3 (23.5), 1.5 (0.5)	0	-	41 (24.1)	243.5 (693.7), 1.4 (0.6)
D-AA	54 (22.8)	65.5 (30.4), 1.4 (0.7)	14 (25.9)	45.4 (17.5), 1.2 (0.4)	2 (15.4)	62.8 (0.0), 1.0 (0.0)	38 (22.4)	72.1 (31.5), 1.5 (0.8)

AA	40 (16.9)	95.4 (48.7), 1.4 (0.5)	17 (31.5)	101.8 (52.5), 1.3 (0.5)	1 (7.7)	52.1 (-), 1.0 (-)	22 (12.9)	92.6 (46.7), 1.5 (0.5)
DA ^b	32 (13.5)	230.4 (433.3), 1.3 (0.5)	10 (18.5)	153.6 (53.2), 1.3 (0.5)	0	-	22 (12.9)	264.3 (518.3), 1.2 (0.4)
HA	29 (12.2)	115.4 (46.9), 1.4 (0.5)	9 (16.7)	128.3 (29.5), 1.4 (0.5)	1 (7.7)	129.5 (-), 1.0 (-)	19 (11.2)	108.9 (53.2), 1.4 (0.5)
Decitabine	27 (11.4)	-, 2.1 (1.3)	5 (9.3)	-, 2.1 (0.8)	1 (7.7)	-, 1.0 (-)	21 (12.4)	-, 2.2 (1.5)
FLAG	26 (11.0)	1929.8 (320.3), 1.1 (0.4)	4 (7.4)	1993.9 (110.0), 1.0 (0.0)	3 (23.1)	1686.1 (559.4), 1.0 (0.0)	19 (11.2)	1952.3 (308.4), 1.2 (0.4)
IAC	23 (9.7)	190.6 (362.3), 1.3 (0.5)	8 (14.8)	120.6 (16.3), 1.0 (0.0)	2 (15.4)	114.4 (4.8), 1.0 (0.0)	13 (7.6)	232.5 (456.2), 1.5 (0.5)
MiDAC	20 (8.4)	2747.1 (906.9), 2.1 (1.0)	6 (11.1)	2306.5 (549.0), 2.0 (0.8)	1 (7.7)	1948.5 (393.7), 2.0 (-)	13 (7.6)	2990.9 (957.4), 2.1 (1.2)
Ara- C+Aza+HHT	17 (7.2)	77.5 (38.7), 1.0 (0.0)	9 (16.7)	90.6 (50.6), 1.0 (0.0)	3 (23.1)	63.4 (1.4), 1.0 (0.0)	5 (2.9)	62.5 (7.3), 1.0 (0.0)

HiDAC	13 (5.5)	5856.9 (634.2), 2.0 (0.7)	4 (7.4)	5549.4 (1117.2), 2.6 (0.7)	0	-	9 (5.3)	5988.7 (213.2), 1.7 (0.5)
Other ^c	105 (44.3)	-	25 (46.3)	-	2 (15.4)	-	73 (42.9)	-
Third	41 (14.2)		13 (22.4)		2 (14.3)		26 (12.0)	
D-AA	7 (17.1)	65.0 (31.9), 1.7 (1.0)	2 (15.4)	61.3 (0.0), 1.0 (0.0)	1 (50.0)	111.3 (-), 1.0 (-)	4 (15.4)	57.9 (30.5), 2.0 (1.1)
Decitabine	6 (14.6)	-, 3.8 (2.3)	1 (7.7)	-, 1.0 (-)	0	-	5 (19.2)	-, 4.0 (2.2)
MA	4 (9.8)	101.1 (24.3), 1.0 (0.0)	0	-	0	-	4 (15.4)	101.1 (24.3), 1.0 (0.0)
Azacitidine	4 (9.8)	-, 1.0 (0.0)	3 (23.1)	-, 1.0 (0.0)	0	-	1 (3.8)	-, 1.0 (-)
AA	3 (7.3)	48.4 (23.6), 1.0 (0.0)	0	-	0	-	3 (11.5)	48.4 (23.6), 1.0 (0.0)
D-MA	3 (7.3)	70.1 (31.7), 1.0 (0.0)	0	-	1 (50.0)	52.1 (-), 1.0 (-)	2 (7.7)	79.2 (39.0), 1.0 (0.0)

HAD	3 (7.3)	117.0 (10.0), 1.0 (0.0)	3 (23.1)	117.0 (10.0), 1.0 (0.0)	0	-	0	-
Other ^c	26 (63.4)	-	4 (30.8)	-	0	-	15 (57.7)	-
Fourth and above	15 (5.2)		4 (6.9)		1 (7.1)		10 (4.6)	
HA	2 (13.3)	53.4 (0.0), 1.7 (0.6)	1 (25.0)	-, 1.0 (-)	-	-	1 (10.0)	53.4 (-), 2.0 (-)
Decitabine	2 (13.3)	-, 1.0 (0.0)	0	-	0	-	2 (20.0)	-, 1.0 (0.0)
IAC	2 (13.3)	92.6 (29.0), 1.0 (0.0)	0	-	0	-	2 (20.0)	92.6 (29.0), 1.0 (0.0)
AA	2 (13.3)	78.8 (47.6), 1.7 (0.6)	1 (25.0)	106.3 (-), 2.0 (-)	0	-	1 (10.0)	23.8 (-), 1.0 (-)
Azacitidine	2 (13.3)	-, 1.7 (0.6)	1 (25.0)	-, 1.0 (-)	0	-	1 (10.0)	-, 2.0 (-)
MAE	1 (6.7)	32.6 (-), 1.0 (-)	0	-	0	-	1 (10.0)	32.6 (-), 1.0 (-)
Ara- C+Aza+HHT	1 (6.7)	53.1 (-), 1.0 (-)	1 (25.0)	53.1 (-), 1.0 (-)	0	-	0	-

MiDAC	1 (6.7)	2125.5 (-), 3.0 (-)	1 (25.0)	2125.5 (-), 3.0 (-)	0	-	0	-
FLAG	1 (6.7)	1018.2 (-), 1.0 (-)	0	-	0	-	1 (10.0)	1018.2 (-), 1.0 (-)
HAD	1 (6.7)	65.8 (-), 1.0 (-)	0	-	0	-	1 (10.0)	65.8 (-), 1.0 (-)
Other ^d	4 (26.7)	-	1 (25.0)	-	1 (7.1)	-	2 (20.0)	-

^aTreatment information was summarized for each regimen and categorized by therapy type. This column summarizes the number of patients who ever received a specific treatment regimen. A patient receiving multiple treatment regimens under one treatment type would be counted for each received treatment regimen; therefore, the percentages under each treatment type may not add up to 100%; ^bDA regimen included DA 7+3, DA 5+2, and other DA. DA 7+3 refers to cytarabine daily for 7 days and daunorubicin daily for 3 days. DA 5+2 refers to cytarabine daily for 5 days and daunorubicin daily for 2 days; ^cOther refers to a combined group of individual regimens used by <5% of patients.

AA, cytarabine and aclarubicin; AML, acute myeloid leukemia; Ara-C, cytarabine; Ara-C+Aza+HHT, cytarabine, azacitidine, and homoharringtonine; DA, daunorubicin and cytarabine; D-AA, decitabine, cytarabine, and aclarubicin; D-MA, decitabine, cytarabine, and mitoxantrone; FLAG, fludarabine, cytarabine, and granulocyte-colony stimulating factor (G-CSF); *FLT3*, FMS-like tyrosine kinase-3, HA, homoharringtonine and cytarabine; HAD, homoharringtonine, cytarabine, and daunorubicin; HiDAC, high-dose cytarabine; IAC, idarubicin, cytarabine, and cyclophosphamide; IQR, interquartile range; MA, cytarabine and mitoxantrone; MAE, mitoxantrone, cytarabine, and etoposide; MiDAC, mid-dose cytarabine; mut, mutated; MUT, mutated; R/R, relapsed or refractory; SD, standard deviation; WT, wild type.